PressOctober 15, 2024 Psyence Group Enters into Debt-for-Equity Swap Agreement with its NASDAQ-Listed Associate, Psyence Biomedical
PressOctober 10, 2024 Clearmind Medicine Announces IRB Approval for FDA First-In-Human Clinical Trial of CMND-100 at Second Clinical Site
PressOctober 10, 2024 Braxia Scientific Announces Voting Results from the Annual General and Special Meeting of Shareholders
PressOctober 10, 2024 Clearmind Medicine : FDA approval for the IND submission to conduct its trial already secured Form 6K
PressOctober 9, 2024 PharmAla to supply the University of Texas, San Antonio, with novel dosage form of LaNeo™ MDMA
PressOctober 9, 2024 MindBio Develops Long Term Shelf-Stable Microdosing Formulation and is Progressing in Multiple Phase 2B Clinical Trials
PressOctober 7, 2024 Bionomics Issues Shareholder Letter Highlighting Recent Achievements and Strategic Vision
PressOctober 7, 2024 Filament Health Announces Issuance of Common Shares to Negev Capital Investments Limited Pursuant to Advisory Agreement
PressOctober 4, 2024 Psyence Biomed Provides Update on Previously Announced Acquisition of Clairvoyant
PressOctober 4, 2024 Awakn Selects Eurofins Discovery for Pharmacology Testing in New Chemical Entity (NCE) Pre-Clinical Program
PressOctober 2, 2024 Lobe Sciences and Alera Pharma Announce Issuance of U.S. Patent for Conjugated Psilocin™
PressSeptember 30, 2024 Incannex Healthcare Inc. Reports Fiscal Full Year 2024 Financial Results and Business Updates
PressSeptember 25, 2024 Cybin to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit
PressSeptember 25, 2024 Red Light Holland Announces NCIB Update and Live Q&A with CEO Todd Shapiro and CFO Jon Szczur on September 26th
PressSeptember 25, 2024 MindBio Therapeutics Enrolls 25th Participant into Landmark Take-Home Microdosing Depression Trial
PressSeptember 25, 2024 Compass Pathways to Participate in Cowen Psychedelics and Novel Mechanisms in Neuropsychiatry Summit
PressSeptember 19, 2024 PharmaDrug’s Sairiyo Therapuetics Announces Initiation of Study Start-Up Activities and Design for Clinical Trial of PD-001 (Patented Reformulated Cepharanthine) for Viral Infectious Diseases
